Gilead Sciences (NASDAQ:GILD) returned 37.56% over the past year through the Nov. 13, 2026 close, while the SPDR S&P 500 ETF Trust (NYSEARCA:SPY), used here as a stand-in for the index, returned 12.25%. That puts Gilead 25.31 percentage points ahead. Over ten years, though, Gilead still trails the index.
Hepatitis C Cures Shrank Their Own MarketFor those unfamiliar, Gilead sells HIV treatments, liver disease drugs and cancer therapies. Its hepatitis C cures, Sovaldi and Harvoni, cured enough patients that the pool of new patients shrank, and sales declined after their peak. To replace that revenue, Gilead bought Kite Pharma in 2017 for about $11.9B to get into cell therapy, then Immunomedics in 2020 for Trodelvy. The COVID drug Veklury gave a temporary lift that has since faded, with third-quarter sales down 69% to $86M.
HIV Prevention Powered a Strong 2026In results filed Oct. 29, 2026, HIV sales rose 18% to $6.249B. Yeztugo, a twice-yearly shot that prevents HIV infection, brought in $305M versus $39M a year earlier. Descovy rose 49%, and Trodelvy rose 42%. Gilead raised 2026 product sales guidance to $31.0-$31.3B.
Gilead Turned $1,000 Into $3,249, While the Index Reached $4,0111-Year Return
5-Year Return
10-Year Return (bought Nov. 30, 2016 at $73.70, dividends reinvested)
By share price alone, the ten-year investment would be worth $2,281. The quarterly dividend rose from $0.47 in late 2016 to $0.82 now, and reinvesting it accounts for the difference. The five-year window started near a low of $56.51. Even after a strong year, Gilead still lags the index over ten years.
The stock trades at about 17 times forward earnings and yields 1.94%. Analysts have an average target of $174.77, with 6 strong buy, 16 buy, 5 hold, and 1 strong sell ratings.
Medicare Pricing Keeps Gilead a Close Call for NowThe outlook depends partly on whether HIV prevention keeps growing and the new cancer drugs deliver, starting with anito-cel, which has an FDA decision date of December 23, 2026. Drug pricing rules are another variable. Medicare’s Biktarvy price takes effect Jan. 1, 2028, and Gilead estimates a net hit of about $1.5 billion to Biktarvy revenue that year. Cash also fell from $10.6B to $6.4B during the acquisition push.
The 2028 Medicare pricing change stays a factor in the outlook. Over ten years, reinvested dividends added to the total return.